Phase I Study Of CC-90010 In Patients With ... - ResearchGate
Access denied
You do not have access to www.researchgate.net.
The site owner may have set restrictions that prevent you from accessing the site.
- Ray ID: 9d9b5e72cc4d1b28
- Timestamp: 2026-03-09 16:13:47 UTC
- Your IP address: 103.110.85.167
- Requested URL: www.researchgate.net/publication/333408969_Phase_I_study_of_CC-90010_in_patients_with_advanced_solid_tumors_and_relapsedrefractory_non-Hodgkin_lymphoma_RR_NHL
- Error reference number: 1020
- Server ID: FL_1244F74
- User-Agent: Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/58.0.3029.110 Safari/537.36 Edge/16.16299
Ray ID: 9d9b5e72cc4d1b28
Client IP: 103.110.85.167
© ResearchGate GmbH. All rights reserved.
Từ khóa » Cc-90010
-
Phase I Study Of CC-90010, A Reversible, Oral BET Inhibitor In ...
-
Phase I Study Of CC-90010, A Reversible, Oral BET Inhibitor In ...
-
A Study To Assess The Safety, Tolerability, Pharmacokinetics And ...
-
Trotabresib (CC-90010) | BET Inhibitor - MedChemExpress
-
BET Inhibitor CC-90010 Shows Activity In Advanced Solid Tumors ...
-
CC-90010, A Reversible, Oral Bromodomain And Extra-terminal (BET ...
-
Phase I Study Of CC-90010 In Patients With ... - ASCO Journals
-
CC-90010 | Selleck | Epigenetic Reader Domain Inhibitor
-
Under Fasting And Fed Conditions, CC-90010 Efficacy Remains ...
-
CTNI-16. TROTABRESIB (CC-90010, BMS-986378), A ...
-
CC-90010 Is A Reversible And Orally Active BET Inhibitor
-
Phase I Study Of CC-90010, A Reversible, Oral BET ... - Europe PMC
-
Cc 90010 Clinical Trials 2022 - Clincosm
-
Phase I Study Of CC-90010 In Patients With Advanced Solid Tumours ...